Product Description
TQB3107 is a protein inhibitor that induces apoptosis and inhibits the proliferation of various tumor cells. (Sourced from: https://clinicaltrials.gov/study/NCT06413953)
Mechanisms of Action: Apoptosis Inducer
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sino Biopharmaceutical
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for TQB-3107](https://pryzm-maps.s3.us-west-2.amazonaws.com/12current_maps.png)
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TQB3107-I-01 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-06-01 |